{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-108996","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.491688+00:00","generated_at":"2026-06-23T03:15:45.404536+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Milestone Pharma announces positive Phase 3 RAPID trial results for etripamil in PSVT","bullets":["Primary endpoint met: 64.3% of etripamil patients converted to sinus rhythm within 30 min vs 31.2% placebo (HR=2.62, p<0.001).","Safety profile consistent with prior trials; no serious AEs related to etripamil; majority of AEs mild (68%) to moderate (31%).","Pooled data show statistically significant reduction in medical interventions and ED visits.","Company plans to submit NDA to FDA in mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-108996","json":"https://secwatch.observer/filing/0001104659-22-108996.json","markdown":"https://secwatch.observer/filing/0001104659-22-108996.md","text":"https://secwatch.observer/filing/0001104659-22-108996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922108996/0001104659-22-108996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922108996/tm2228338d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:15:45.404536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}